Mandate Vinge advises IRLAB Therapeutics in connection with share issues

December 13, 2019

Vinge advises IRLAB Therapeutics in connection with a directed share issue of SEK 70 million and a rights issue of approximately SEK 145 million.

The directed share issue was subscribed for by a number of institutional and qualified investors on the basis of an accelerated book building process. The rights issue is expected to be completed during the first quarter of 2020.

IRLAB Therapeutics is a research and development company, listed on Nasdaq First North Premier Growth Market, focused on development of novel therapies for the treatment of neurodegenerative diseases, in particular Parkinson’s disease and dementia.

Vinge’s team has consisted of Dain Hård Nevonen, Nils Fredrik Dehlin, Stephanie Stiernstedt, Stojan Arnerstål, Anna Thoms and Maria Schultzberg.

Covid-19: Checklist of legal issues for companies

The Covid-19 situation has had a material negative effect on a large number of Swedish businesses and it has also led to considerable fluctuations on the financial markets. We have gathered together a number of questions and answers which we frequently encounter in our practice to help companies navigate the situation.
March 27, 2020

Covid-19 and its impact on international trade

Vinge’s experts within trade and shipping summarise some observations on how Corona as of today impact international trade.
March 27, 2020

Brexit and cross-border telecommunications services

The Transition Period entered into force immediately upon the United Kingdom’s withdrawal from the European Union on 31 January 2020. During this period, EU law will continue to be applicable to and within the UK. What is to follow the Transition Period is uncertain and subject to ongoing negotiations between the EU and the UK. However, it is likely that the regulation of cross-border telecommunications services will be affected. In this context, this note discusses various implications of Brexit.
March 25, 2020